RESOURCES - PRESS RELEASES

Previon, a leader in healthcare communication and diagnostic solutions, has closed a second financing round with RevTek Capital. This strategic funding accelerates Previon’s nationwide expansion and innovation in self-service communication tools and at-home diagnostic kit services. With a 30-year legacy in healthcare support, Previon continues to streamline patient engagement and compliance for major care providers.

Apex Biologix, a pioneer in regenerative medicine, has closed a strategic financing round with RevTek Capital to support its rapid growth and expand its suite of FDA-cleared solutions, including the groundbreaking XCELL PRP System. With this funding, Apex will scale its transformative technologies and empower more physicians across the U.S. RevTek’s investment reflects a shared vision for innovation, growth, and impact in healthcare.

In a significant move for its growth strategy, Origo has successfully closed financing with RevTek Capital. This partnership aims to bolster Origo’s market presence and unlock new opportunities for innovation and expansion.

CUDDLY has successfully closed a financing deal with RevTek Capital, marking a significant step in its mission to drive innovation and expand its market presence. This partnership is set to bolster CUDDLY’s capabilities and accelerate its growth trajectory in the competitive tech landscape.

Coreware has successfully closed a financing deal with RevTek Capital, marking a significant step in its mission to drive innovation and expand its market presence. This partnership is set to bolster Coreware’s capabilities and accelerate its growth trajectory in the competitive tech landscape.

Previon has successfully closed a financing deal with RevTek Capital, marking a significant step in its mission to drive innovation and growth in the tech sector. This partnership aims to bolster Previon’s capabilities and expand its market reach.

Cymbiotika has successfully secured $30 million in debt financing from RevTek Capital, a leading provider of strategic capital for high-growth companies. This financing will enable Cymbiotika to expand into retail, enter the Canadian market, and enhance infrastructure to support its growing operations. The collaboration with RevTek Capital will also drive product innovation and increase operational efficiency. This investment is expected to accelerate the company’s growth trajectory, both in revenue and EBITDA, in the coming years. RevTek Capital offers funding opportunities ranging from $2 million to $20 million+ for companies with predictable recurring revenue, helping businesses like Cymbiotika achieve their long-term goals.